Post-COVID Digestive Issues: What to Know About IBS After Infection

COVID-19 can manifest in various ways, and for many individuals, recovery has not meant a complete return to normal. The body's resilience is evident in its ability to cope with ongoing digestive issues—such as bloating, pain, and unpredictable bowel habits—that have remained as lasting reminders of the illness.

New research suggests a strong connection between COVID-19 and the development of Irritable Bowel Syndrome (IBS), a condition that can make everyday life uncomfortable. Understanding how COVID-19 may affect the gut, recognizing its symptoms, and identifying effective management strategies are crucial steps toward restoring digestive health. Early detection and appropriate care are key to supporting recovery and well-being.

Post-Viral IBS: A Known Phenomenon, Now Linked to COVID-19.

Post-viral IBS, also known as post-infectious IBS, is a recognized condition that can develop after a viral or bacterial infection of the gastrointestinal (GI) tract. Individuals who recover from gastroenteritis may continue to experience chronic digestive symptoms such as bloating, abdominal pain, diarrhea, or constipation—hallmarks of IBS—even after the original infection has resolved.

COVID-19 frequently presents with acute gastrointestinal symptoms, and growing evidence suggests that the virus may contribute to a post-infectious IBS pattern in some individuals. COVID-19 affects more than just the respiratory system; like other viruses, it can also impact the digestive tract. The virus interacts with cells lining the gut and may disrupt the intestinal microbiome, leading to an imbalance that can trigger or exacerbate digestive symptoms.

Symptoms of Post-COVID IBS: What to Look For.

Abdominal Pain and Cramping

Ongoing abdominal pain or cramping is among the most frequently reported gastrointestinal complaints following COVID-19.

Changes in Bowel Habits

Some individuals experience persistent diarrhea, constipation, or alternating patterns of both, sometimes lasting for several months post-infection.

Bloating and Gas

Reports of bloating, excessive gas, and abdominal discomfort—even after consuming previously well-tolerated foods—have become increasingly common.

Overlap with Long COVID

Distinguishing between IBS-related digestive symptoms and those associated with long COVID can be challenging. Fatigue, brain fog, and other systemic issues often accompany gastrointestinal symptoms, making diagnosis more complex.

Potential Causes: Why COVID-19 May Trigger IBS

Gut Microbiome Disruption

COVID-19 may disrupt the balance of beneficial bacteria in the gut, altering nutrient absorption and impacting immune regulation. These changes can influence digestive health and overall wellness.

Inflammation and Gut Motility

The inflammation triggered by COVID-19 can persist in the gastrointestinal tract, affecting the movement of food through the intestines, either speeding it up or slowing it down.

Nervous System Involvement

The gut-brain axis, which connects the digestive system and the nervous system, can be affected by the stress or inflammation caused by the virus, contributing to gastrointestinal disturbances.

Small Intestinal Bacterial Overgrowth (SIBO)

Some individuals may develop SIBO following COVID-19 infection. This condition involves an overgrowth of bacteria in the small intestine, which can worsen IBS symptoms such as bloating, pain, and irregular bowel movements.

Diagnosing Post-COVID IBS: What to Expect

Medical History and Symptom Review

Healthcare providers typically begin by reviewing a patient's symptom history and any changes in health or digestion that have occurred following a COVID-19 diagnosis. Noting the timing of symptoms in relation to a recent infection can help establish a connection.

Diagnostic Tests

There is no single test for IBS. Diagnosis is often based on clinical history, symptom patterns, and the exclusion of other conditions such as celiac disease or inflammatory bowel disease. Tests may include blood panels, stool analyses, or imaging, depending on the presentation and severity of symptoms.

The Rome IV Criteria

The Rome IV criteria commonly guide diagnosis, a standardized set of guidelines used to identify IBS based on symptom duration, type, and frequency. Functional gastrointestinal disorders (FGIDs), such as IBS, are diagnosed primarily through symptom analysis, as structural or biochemical abnormalities are typically absent in conventional testing.

Managing Post-COVID IBS: Treatment and Strategies

Dietary Changes: Low FODMAP and More

A Low FODMAP diet, which limits certain fermentable carbohydrates, is effective in reducing symptoms such as bloating, gas, and irregular bowel movements.

Stress Management

Mindfulness practices, including meditation, yoga, and deep breathing exercises, have demonstrated benefits in managing stress-related gastrointestinal symptoms. These practices can help regulate the gut-brain axis and reduce symptom severity.

Probiotics and Prebiotics

Supplementing with probiotics may help restore balance to the gut microbiome. Selecting evidence-based strains that match specific symptoms is crucial for achieving optimal results.

Medications

Pharmacologic options may include anti-diarrheal medications, laxatives, or antispasmodics, depending on the individual symptom profile. Treatment should be personalized based on clinical evaluation.

Psychological Therapies

Cognitive behavioral therapy (CBT) and gut-directed hypnotherapy have been shown to improve symptom control and quality of life in individuals with IBS.

Conclusion

Post-COVID IBS highlights the lasting impact that COVID-19 can have on the gastrointestinal system. Ongoing digestive symptoms should not be dismissed as minor or imagined, especially when they persist after infection.

Increased awareness of this condition allows for earlier recognition and targeted interventions. A combination of dietary strategies, stress management techniques, microbiome support, and personalized medical care offers a comprehensive approach to managing symptoms and promoting recovery. For individuals experiencing persistent digestive issues, consulting a healthcare professional remains essential for an accurate diagnosis and effective treatment planning.

1. _{Blackett, J. W., Li, J., & Jodorkovsky, D. (2022). Prevalence and risk factors for post-infection irritable bowel syndrome following COVID-19 infection. Gastroenterology, 162(5), 1669–1671. https://doi.org/10.1053/j.gastro.2022.02.051}

2. _{Drossman, D. A., & Hasler, W. L. (2016). Rome IV—Functional GI Disorders: Disorders of gut-brain interaction. Gastroenterology, 150(6), 1257–1261. https://doi.org/10.1053/j.gastro.2016.03.035}

3. _{Ford, A. C., Moayyedi, P., Chey, W. D., Harris, L. A., Lacy, B. E., Saito, Y. A., Quigley, E. M. M., & ACG Task Force on Management of Irritable Bowel Syndrome (2018). American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome. The American journal of gastroenterology, 113(Suppl 2), 1–18. https://doi.org/10.1038/s41395-018-0084-x} 

4. _{Ghoshal, U. C., Ghoshal, U., Rahman, M. M., Mathur, A., Rai, S., Akhter, M., Mostafa, T., Islam, M. S., Haque, S. A., Pandey, A., Kibria, M. G., & Ahmed, F. (2022). Post-infection functional gastrointestinal disorders following coronavirus disease-19: A case-control study. Journal of gastroenterology and hepatology, 37(3), 489–498. https://doi.org/10.1111/jgh.15717} 

5. _{Mayer, E. A., Tillisch, K., & Gupta, A. (2015). Gut/brain axis and the microbiota. The Journal of clinical investigation, 125(3), 926–938. https://doi.org/10.1172/JCI76304} 

6. _{Nalbandian, A., Sehgal, K., Gupta, A., Madhavan, M. V., McGroder, C., Stevens, J. S., Cook, J. R., Nordvig, A. S., Shalev, D., Sehrawat, T. S., Ahluwalia, N., Bikdeli, B., Dietz, D., Der-Nigoghossian, C., Liyanage-Don, N., Rosner, G. F., Bernstein, E. J., Mohan, S., Beckley, A. A., Seres, D. S., … Wan, E. Y. (2021). Post-acute COVID-19 syndrome. Nature medicine, 27(4), 601–615. https://doi.org/10.1038/s41591-021-01283-z} 

7. _{Spiller, R., & Garsed, K. (2009). Postinfectious irritable bowel syndrome. Gastroenterology, 136(6), 1979–1988. https://doi.org/10.1053/j.gastro.2009.02.074} 

8. _{Yeoh, Y. K., Zuo, T., Lui, G. C., Zhang, F., Liu, Q., Li, A. Y., Chung, A. C., Cheung, C. P., Tso, E. Y., Fung, K. S., Chan, V., Ling, L., Joynt, G., Hui, D. S., Chow, K. M., Ng, S. S. S., Li, T. C., Ng, R. W., Yip, T. C., Wong, G. L., … Ng, S. C. (2021). Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut, 70(4), 698–706. https://doi.org/10.1136/gutjnl-2020-323020} 

9. _{Zuo, T., Zhang, F., Lui, G. C. Y., Yeoh, Y. K., Li, A. Y. L., Zhan, H., Wan, Y., Chung, A. C. K., Cheung, C. P., Chen, N., Lai, C. K. C., Chen, Z., Tso, E. Y. K., Fung, K. S. C., Chan, V., Ling, L., Joynt, G., Hui, D. S. C., Chan, F. K. L., Chan, P. K. S., & Ng, S. C. (2020). Alterations in gut microbiota of patients with COVID-19 during time of hospitalization. Gastroenterology, 159(3), 944–955.e8. https://doi.org/10.1053/j.gastro.2020.05.048}